1 completed, 1 terminated. 2 Phase 3, 1 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
| Phase 2 | 1 | Completed 1 |
Follow FGFR2 Gene Mutation: new trials by email Literature Review of FGFR2 Gene Mutation trials Research Report on FGFR2 Gene Mutation
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations BGJ398, Gemcitabine, Cisplatin - Advanced Cholangiocarcinoma, FGFR2 Gene Mutation | Phase 3 | Terminated | QED Therapeutics, a BridgeBio company | 48 | 2019-12-27 | 2024-05-08 |
| Lung-MAP: AZD4547 as Second-Line Therapy in Treating FGFR Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer Docetaxel, FGFR Inhibitor AZD4547, Laboratory Biomarker Analysis - FGFR1 Gene Amplification, FGFR1 Gene Mutation | Phase 2 / Phase 3 | Completed | SWOG Cancer Research Network | 43 | 2014-10-01 | 2021-05-27 |
Adenocarcinoma (1) · Carcinoma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms, Glandular and Epithelial (1)
AZD4547 (1) · Cisplatin (1) · Docetaxel (1) · Gemcitabine (1) · infigratinib (1)
QED Therapeutics, a BridgeBio company (1) · SWOG Cancer Research Network (1)
Canada (2) · United States (2) · Australia (1) · Belgium (1) · China (1) · France (1) · Germany (1) · Italy (1) · Portugal (1) · Puerto Rico (1) · South Korea (1) · Spain (1) · Taiwan (1) · Thailand (1) · United Kingdom (1)
Vassiliki Papadimitrakopoulou (1)
2018 (1), U10CA180888 (1)